Company Overview and News

Palmer notches $200m court win against Chinese

Businessman Clive Palmer has described his victory in the long-running royalties battle against Chinese state-owned government enterprise Citic Pacific in the Pilbara as a “win for all Australians”.

Clive Palmer wins longstanding Pilbara iron ore royalty claim

Businessman Clive Palmer's company Mineralogy has won a Supreme Court claim for $US150 million in unpaid royalties against two Citic Pacific subsidiaries over a Pilbara iron ore project.

DCH and CITIC Pacific establish an investment fund

2017-10-23 marketwired
HONG KONG, CHINA--(Marketwired - Oct 23, 2017) - Dah Chong Hong Holdings Limited ("DCH") (HKSE: 1828) announced today that it will partner with its parent company, CITIC Pacific Limited ("CITIC Pacific"), a wholly-owned subsidiary of CITIC Limited, to establish an investment fund -- Tamar Alliance ("Tamar Alliance Fund" or "Fund"). The Tamar Alliance Fund seeks long term capital appreciation through investments in companies in the consumer or healthcare sector.

Sino Land pays record HK$1.38 billion for site in Ma On Shan

2017-07-21 scmp
Sino Land has won a residential land plot in Ma On Shan, in Hong Kong’s New Territories, for HK$1.38 billion, setting a new record for the area.

Alliance extends contract with Citic Pacific

Aviation services company Alliance Airlines has extended its provision of air charter services for CITIC Pacific Mining in the Pilbara region, having signed a new five year contract.  

Palmer in court for $US150m Citic royalty fight

Clive Palmer has dismissed the gathering of CITIC Pacific Mining employees outside the Supreme Court of Western Australia this morning, ahead of the start of the trial between his private company, Mineralogy, and Citic over royalties, as a ‘Chinese tactic’.

Clive Palmer in Perth Supreme Court over Pilbara port bid

A trial has begun in the West Australian Supreme Court over a royalty dispute between mining company Citic Pacific and Clive Palmer's Mineralogy.

Palmer in court for $US150m royalty fight with Citic

Clive Palmer has made an appearance in the Supreme Court of Western Australia for the start of the trial between his private company Mineralogy and estranged joint venture partner CITIC Pacific Mining over royalties at the Sino Iron magnetite project near Karratha.

VPower promotes ‘super-connector’ role on power projects along the new Silk Road routes

2017-06-05 scmp
Company already in talks to form a partnership with China’s oldest and largest conglomerate Citic Ltd to scout for projects in Southeast Asia

Minority shareholders urge securities watchdog to appeal Citic misconduct ruling

2017-04-27 scmp
Lawmaker James To Kun-sun has helped about 200 Citic small shareholders who suffered losses to seek redress

Clive Palmer goes quietly from politics

He's been big in every sense - in business, in politics, above all in his outrageous zest for life.

Hong Kong Tribunal Finds No Misconduct With Citic, Directors - Bloomberg

2017-04-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Dah Chong Hong seeks to remake business to reverse profit slump

2017-02-27 scmp
Hong Kong’s leading food retailer and importer of Bentley and Infiniti cars will depend on acquisitions, a rebalancing of its business and expansion into Southeast Asia to reverse its earnings slump, its chairman said.

At least 12 bidders for Ap Lei Chau residential site

2017-02-17 scmp
Located next to the major housing estate, South Horizons, site estimated to fetch as much as HK$11.4 billion

Pilbara project hit by $US1bn impairment

Iron ore miner Citic Pacific will cop a write down of up to $US1 billion on its Sino Iron magnetite operation in the Pilbara, less than a year after the facility completed commissioning.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...